Category - Markets

Markets

William Blair starts Pieris Pharma at OP

William Blair initiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with an “outperform” rating. The stock closed $7.46 on Jan. 16. Analyst Matthew Phipps writes that the company’s Anticalin platform continues to...

January 17, 2018

Markets

CIBC-favored health care stocks for 2018

For 2018, CIBC World Markets is recommending investors hold a basket of healthcare stocks that include a combination of more speculative small and midcap companies with selected large caps. Analyst Prakash Gowd writes...

January 16, 2018

Markets

Maxim starts Immune Pharma at buy; PT $3

Maxim Group launched coverage of Immune Pharmaceuticals (NASDAQ:IMNP) with a “buy” rating and $3 price target. The stock closed at 57 cents on Jan. 4. Immune’s bertilimumab is a monoclonal antibody (mAb), targeting...

January 5, 2018

Markets

Leerink starts Regulus Therapeutics at OP; PT $2

Leerink initiated coverage on Regulus Therapeutics (NASDAQ:RGLS) with an “outperform” rating and 12-month price target of $2. The stock closed at $1.18 on Jan. 4. “We believe that following numerous clinical setbacks...

January 5, 2018

Markets

Ladenburg starts UroGen Pharma at buy; PT $50

Ladenburg Thalmann initiated coverage of UroGen Pharma (NASDAQ:URGN) with a “buy” rating and $50 price target. The stock closed at $37.21 on Dec. 29. UroGen is developing RTGel, a reverse, thermally-triggered hydrogel...

January 2, 2018

Markets

Roth starts Genfit at buy; PT €116

Roth Capital Partners launched coverage of Genfit (PSE:GNFT) with a “buy” rating and 12-month price target of €116. The stock closed at €22.09 on Dec. 20. “A spearhead in NASH drug development, Paris-based Genfit is...

December 21, 2017

Markets

Roth starts Moleculin Biotech at buy; PT $8

Roth Capital Partners initiated coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $8 price target. The stock closed at $1.69 on Dec. 20. “Our Moleculin bull thesis is based solely on its liposomal...

December 21, 2017

Markets

BTIG ups ConforMIS to buy; PT $4

BTIG upgraded ConforMIS (NASDAQ:CFMS) to “buy” from “neutral” with a price target of $4. The stock was quoted at $2.58, up 30 cents, in afternoon trading on Dec. 20. ConforMIS designs and manufactures customized knee...

December 20, 2017

Markets

Mackie ups Organigram price target to $5

Mackie Research raised its price target for Organigram Holdings (TSX:OGI) to $5 from $4 after the company completed a $57.5-million offering of units at a price of $3.50 a unit. The stock closed at $3.70 on Dec. 18...

December 19, 2017

Markets

Leerink outlines 2018 outlook of healthcare shares

Leerink is recommending that healthcare investors, after a market-beating 2017, look for ways to keep up with what will likely be a strong broader stock market in 2018. “We encourage use of higher-beta healthcare and...

December 18, 2017

Category - Markets

Subscribe